Please assess the completion status of the following clinical trial:

Trial Title: Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years but \<60 years; body mass index ≥18 but \<30 kg/m2;~2. Scheduled to undergo elective bimaxillary surgery under general anesthesia;~3. Planned to use patient-controlled intravenous analgesia (PCIA) after surgery;~4. Provide written informed consents.~Exclusion Criteria:~1. Presence of glaucoma;~2. Allergic to penehyclidine, atropine, scopolamine or other anticholinergic drugs;~3. Acute or chronic nausea and/or vomiting, or gastrointestinal motility disorders before surgery;~4. Preoperative antiemetic therapy within 12 hours;~5. History of schizophrenia, Parkinson's disease or profound dementia, or language barrier;~6. Severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (requirement of renal replacement therapy before surgery) or American Society of Anesthesiologists physical status ≥IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): For patients in the control group, a dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron 10 mg, diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
- Single injection group (Type: EXPERIMENTAL): For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
- Continuous infusion group (Type: EXPERIMENTAL): For patients in this group, a dose of penehyclidine (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).